# US 2016/0252529 A1 · Diagnostic method for urinary tract infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252529 A1
- Document ID: US20160252529A1
- Status: Published application
- Kind: A1
- Application number: 15/153,570
- Filed: 2016-05-12
- Published: 2016-09-01
- Earliest claimed: 2011-02-07
- Assignees: Hansa Medical AB
- Applicants: Hansa Medical AB
- Inventors: Lars BJÖRCK; Bertil Christensson; Heiko Herwald; Adam Linder; Per Åkesson
- Web page: https://patentgrep.com/patent/US20160252529A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- C07K 16/18: against material from animals or humans
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- G01N 2400/40: Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
- G01N 2800/348: Urinary tract infections
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.

## Claims

### Claim 1

A method of identifying whether or not an individual has a urinary tract infection, which method comprises measuring HBP in the individual and thereby determining whether or not the individual has a urinary tract infection.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the HBP is measured in a sample taken from the individual.

### Claim 3 (depends on 2)

A method according to claim 2, wherein the sample is a fluid sample, preferably a urine sample.

### Claim 4 (depends on 2)

A method according to claim 2, wherein determining whether or not the individual has a urinary tract infection comprises determining whether or not the concentration of HBP is greater than 15 ng/ml, preferably greater than 25 ng/ml, more preferably greater than 35 ng/ml, and most preferably greater than 50 ng/ml in the sample.

### Claim 5 (depends on 2)

A method according to claim 2, wherein the level or concentration of HBP in the sample is increased by at least 3 fold or 4 fold relative to the baseline level or concentration of HBP.

### Claim 6 (depends on 1)

A method according to claim 1, wherein the individual is suspected of having a urinary tract infection.

### Claim 7 (depends on 1)

A method according to claim 1, wherein the individual is a mammal.

### Claim 8 (depends on 7)

The method of claim 7, wherein the mammal is a human.

### Claim 9

An agent for the detection of HBP for use in determining whether or not an individual has a urinary tract infection.

### Claim 10 (depends on 9)

An agent according to claim 9, wherein the agent comprises an HBP-specific antibody, or an HBP-binding fragment thereof.

### Claim 11 (depends on 1)

A method of treating an individual for a urinary tract infection, comprising;
(i) determining whether or not an individual has a urinary tract infection using a method according to claim 1; and
(ii) administering to an individual identified in (i) as at risk, a therapeutically effective amount of an agent suitable for the treatment of a urinary tract infection.

### Claim 12 (depends on 11)

The method of claim 11, wherein the agent suitable for the treatment of urinary tract infection is an antibiotic.

### Claim 13 (depends on 1)

A method according to claim 1, where the HBP concentration provides information on the severity of infection.

### Claim 14

A test kit for use in a method for determining whether or not an individual has a urinary tract infection, which test kit comprises an agent for the detection of HBP in an individual.
